Month: March 2025

SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025.Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million. GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year’s first quarter. Non-GAAP diluted EPS of $0.92, up $0.07 from last year’s first quarter. See “Reconciliation of Selected GAAP Results to Non-GAAP Results” below.Commenting on the results, Al White, Cooper’s President and CEO said, “We started the year on a positive note meeting our revenue expectations and exceeding our operational targets. Moving forward,...

Dallas, Texas, March 06, 2025 (GLOBE NEWSWIRE) — Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $13.2 million, or $.12 per share, in the fourth quarter of 2024 compared to a net loss of $5.3 million, or $.05 per share, in the fourth quarter of 2023. For the full year of 2024, Kronos Worldwide reported net income of $86.2 million, or $.75 per share, compared to a net loss of $49.1 million, or $.43 per share, for the full year of 2023. Net income decreased in the fourth quarter 2024 compared to the fourth quarter of 2023 primarily due to increases in the Company’s income tax expense resulting from (i) final tax regulations on the treatment of certain currency translation gains and losses, which resulted in a non-cash deferred income tax expense of $16.5 million ($.14 per share) and (ii) the recognition of a deferred...

VIRGINIA CITY, Nev., March 06, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2024 results, 2024 summary achievements, and our 2025 business outlook. “As of today, we achieved all of our previously published 2024 objectives for both our metals and fuels segments, including fully commissioning, operating and establishing market leadership in photovoltaic recycling, that is now rapidly growing and expanding into full industry-scale, and fuels, who has executed multiple, future revenue generating commercial agreements for industry-scale development projects, including offtakes, supply of feedstocks and joint development agreements with operationally experienced, technologically sophisticated and well capitalized customers and partners,” stated Corrado De Gasperis,...

ISSAQUAH, Wash., March 06, 2025 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the second quarter (twelve weeks) and the first 24 weeks of fiscal 2025, ended February 16, 2025. Net sales for the quarter increased 9.1 percent, to $62.53 billion, from $57.33 billion last year. Net sales for the first 24 weeks increased 8.3 percent, to $123.52 billion, from $114.05 billion last year. Comparable sales for the second quarter and first 24 weeks of fiscal 2025 were as follows:  12 Weeks   12 Weeks   24 Weeks   24 Weeks      Adjusted*       Adjusted*U.S. 8.3%   8.6%   6.8%   7.9%Canada 4.6%   10.5%   5.2%   8.6%Other International 1.7%   10.3%   3.2%   8.7%               Total Company 6.8%   9.1%   6.0%   8.1%               E-commerce 20.9%   22.2%   17.1%   17.9%*Excluding...

– Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 – – CX-801 (PROBODY® Interferon-alpha 2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 – – Maintained financial strength with cash runway into Q2 2026 – – Company to host conference call today at 2 p.m. PST / 5 p.m. EST – SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced 2024 financial results and provided a business update. “Throughout 2024 we continued to advance and prioritize our multi-modality clinical pipeline with disciplined capital...

Fourth Quarter Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024 Fourth Quarter Gross Profit Margin of 50.2%, up 140 basis points from 48.8% in the third quarter of 2024 Full Year 2024 Net Cash provided by continuing operations of $38.0 million and Free Cash Flow1 of $28.6 million 10th consecutive quarter of positive Cash Flow from continuing operations and 6th consecutive quarter of positive Free Cash Flow1 TORONTO, March 06, 2025 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the fourth quarter and full year ended December 31, 2024. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles...

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track designation for the treatment of PDAC and Rare Pediatric Disease designation for retinoblastoma – – Received guidance from the FDA and EMA on Phase 3 pivotal trial design for VCN-01 in combination with standard-of-care chemotherapy for metastatic PDAC – –– As of December 31, 2024, Theriva Biologics reports $11.6 million in cash, which is expected to provide runway into Q3 2025 – ROCKVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported...

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, preclinical data to be presented at the 2025 AAD Annual Meeting; Phase 1 initiation expected in Q3 2025, with PK data in 1H 2026 Successful go-public transaction and over $475 million raised in 2024 $394 million of cash, cash equivalents, and marketable securities at year-end 2024, projected to fund company through 2027, over one year past anticipated ORKA-001 Phase 2a data in psoriasis MENLO PARK, Calif.,, March 06, 2025 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing...